B of A Securities Downgrades FibroGen to Neutral, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry downgrades FibroGen (NASDAQ:FGEN) from Buy to Neutral and lowers the price target from $29 to $4.
June 26, 2023 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FibroGen downgraded to Neutral by B of A Securities, with price target reduced from $29 to $4.
The downgrade from Buy to Neutral and the significant reduction in price target by B of A Securities analyst Jason Gerberry indicate a negative outlook for FibroGen's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100